Poor
Needs Revision
Patient Risk:
Moderate
Summary
The response correctly recognizes that the supplied label supports stroke-risk reduction, antiplatelet activity, gastrointestinal symptoms, gastrointestinal bleeding, and NSAID-associated bleeding risk. However, it introduces numerous claims from label sections that were not supplied, references external OTC aspirin labeling, and overstates the label's support for aspirin-related ulceration.
Category Scores
Accurate Statements
The classifications of pain-relief and fever-reduction claims as absent are appropriate for the supplied prescription aspirin/extended-release dipyridamole label.
Section 1 identifies only reduction of stroke risk in patients with prior transient ischemia or completed ischemic stroke due to thrombosis.
The claim that aspirin is used to prevent blood clots is broader than the supplied indication.
Sections 1 and 12.1 support antithrombotic antiplatelet activity and stroke-risk reduction due to thrombosis, not prevention of all blood clots.
Bloating is not identified in the supplied label's gastrointestinal side-effect description.
Section 5.1 lists stomach pain, heartburn, nausea, vomiting, dyspepsia, and gross gastrointestinal bleeding.
The response correctly notes that food-related administration is not described as reducing stomach irritation.
Sections 2 and 12.3 state that the capsules may be taken with or without food and describe pharmacokinetic effects, without claiming gastric protection.
The response correctly identifies that the supplied label emphasizes bleeding risk and does not make a general statement that aspirin is safe when taken as directed.
Section 5.1 warns that aspirin and extended-release dipyridamole increases the risk of bleeding.
Unsupported Statements
The label states that aspirin can cause gastric mucosal irritation, bleeding, and ulceration.
The supplied text states that aspirin should be avoided in patients with active peptic ulcer disease because of gastric mucosal irritation and bleeding, and advises alertness for signs of ulceration. It does not clearly state that aspirin causes ulceration.
The reviewed claims omit contraindications such as active pathological bleeding, hypersensitivity to aspirin or dipyridamole, or aspirin/NSAID-induced asthma, rhinitis, or nasal polyps.
The supplied Contraindications section is empty, so these specific contraindications are not supported by the available label text.
The response omits pregnancy risks, including third-trimester avoidance, ductus arteriosus closure, and oligohydramnios.
The cited pregnancy sections were not supplied, and these details cannot be established from the available label.
The response omits pediatric safety information, including lack of established safety and effectiveness and risk of Reye's syndrome.
The cited pediatric section was not supplied.
The response omits interactions involving adenosine or antihypertensive-related considerations.
These interactions are not described in the supplied sections. The available text supports bleeding-risk interactions involving anticoagulants, antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic NSAID use.
The classifications would be incorrect for FDA-approved OTC aspirin labels that include analgesic and antipyretic uses.
This relies on external labeling and is outside the supplied prescribing information.
Contradictions
Important Omissions
The response does not clearly distinguish between information actually present in the supplied label and information it attributes to unavailable sections.
Importance:
High
The response does not mention the specific supplied dosing and administration details when recommending evaluation of omissions: one capsule orally twice daily, morning and evening, swallowed whole, with or without food, and not interchangeable with individual components.
Importance:
Moderate
The response does not include the supplied label's specific bleeding-risk factors and intracranial and gastrointestinal bleeding event-rate information when discussing the hemorrhage omission.
Importance:
Moderate
The response does not acknowledge the supplied geriatric wording precisely: no overall safety or effectiveness differences were observed, although greater sensitivity in some older individuals cannot be ruled out.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response appropriately emphasizes bleeding and gastrointestinal risks, but its unsupported assertions about contraindications, pregnancy, pediatric use, and additional drug interactions could misrepresent the supplied label and lead to inaccurate safety conclusions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The response cites and asserts details from label sections not supplied and uses external OTC aspirin labeling as a qualification.
Suggested Improvement
Restrict the assessment to the supplied sections. Describe ulceration as a concern for which the label advises vigilance rather than stating that the label explicitly says aspirin causes ulceration, and omit unsupported contraindication, pregnancy, pediatric, and interaction details.